Drug Type in vivo CAR-T therapy |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United States | 06 Dec 2025 | |
| Autoimmune Diseases | Preclinical | China | 06 Dec 2025 | |
| Refractory Multiple Myeloma | Preclinical | United States | 06 Dec 2025 | |
| Refractory Multiple Myeloma | Preclinical | China | 06 Dec 2025 | |
| Relapse multiple myeloma | Preclinical | United States | 06 Dec 2025 | |
| Relapse multiple myeloma | Preclinical | China | 06 Dec 2025 |





